

PI Name: Andreas Buhr

Grant Key: 2-IND-2018-672-I-X

Institution Name: Ypsomed AG

Grant Status: Active Grant

Project Duration: 01-July-2018 to 31-December-2023

Mechanism: Industry Development and Discovery Program (IDDP)

Project Contract Amount: \$500,000.00

** Total Grant award amount may vary depending on budget adjustments and it is contingent upon research progress and availability of JDRF research funds.*

Project Title:

mylife YpsoPump for open-protocol automated insulin delivery

Objective:

The objective of this project is to support the development of the next generation mylife YpsoPump supporting open-protocol automated insulin delivery by third-party cell phone based applications and/or devices via secure , well documented, and verified communication.

Background/Rationale:

mylife YpsoPump is an easy-to-learn, easy-to-use insulin pump system featuring all essential functions of insulin pump therapy. Thanks to its icon-based menu and the modern touch screen, mylife YpsoPump is extremely easy and intuitive to operate. In addition, the compact and lightweight design makes it a discreet companion in everyday situations for children, adolescents and adults. A pre-filled insulin cartridge of a major insulin manufacturer allows quick and convenient cartridge change. The self-filled mylife Reservoir is compatible with all modern insulin analogues. Bluetooth low energy integration enables wireless connection to the mylife Software and the mylife App. This app features a bolus calculator, logbook functionality and reports on the go. With this wireless linking of insulin pump, blood glucose meter and therapy management solution, Ypsomed is taking an important step in the direction of connected diabetes management. The Bluetooth capabilities of the products will also allow integration of a continuous glucose monitoring (CGM) data and automated insulin delivery functionality with the aim to improve outcomes and reduce burden for people with T1D. The mylife YpsoPump system has been launched in Europe in 2016. The product is currently available in 10 European countries (status as of January 2018). The launch plan of the mylife YpsoPump system does include more than 10 additional countries including Canada and the US in 2018/19. mylife YpsoPump submission to the US Food and Drug Administration is planned for May/ June 2018.

Description of the Project:

.

Anticipated Outcome:

The next generation mylife YpsoPump supporting open-protocol automated insulin delivery will be developed and submitted for health authority approvals in major markets.

Relevance to Type I Diabetes:

Automated insulin delivery with the next generation mylife YpsoPump supporting open-protocol automated insulin delivery is expected to improve outcomes and reduce burden for people with T1D.

